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Background
Hypercalcemia is a common complication of adult malig-
nancies, but uncommon in childhood cancers. The
mechanism leading to hypercalcemia varies with the pri-
mary tumour and can include the following: 1) Increased
osteoclastic activity at the site of the tumour in the bone
marrow 2) A paraneoplastic phenomenon secondary to
PTH-related peptide (PTHrP) secretion or 1,25–dihydrox-
yvitamin D by the tumour.
Patients with serum calcium above 3.5 mmol/L tend to
be symptomatic and require prompt treatment. The
symptoms are generally non-specific and include
lethargy, nausea, vomiting, constipation and abdominal
pain. Left untreated, hypercalcemia can progress to stu-
por and coma.
Case Presentation
A 3-year-old girl presented with prolonged fever, hepa-
tosplenomegaly, pancytopenia and multiple osteolytic
lesions. She experienced significant weight loss of 5 kg
over the past one month associated with anorexia and
began to develop persistent daily fever up to 39.5°C with
severe pruritus, constipation and irritability.
She was diagnosed to have Ebstein Barr Virus (EBV)-
induced T-cell Lymphoproliferative disorder. However,
she developed severe symptomatic hypercalcemia of
3.76 mmol/L associated with the paraneoplastic syn-
drome of an elevated PTH-related peptide, which was
successfully treated with intravenous pamidronate
(0.5 mg/kg administered as 2 doses), after conventional
therapy with hydration and forced saline diuresis failed.
Her serum calcium began to normalize to 2.3 mmol/L
2 days after pamidronate administration, with improve-
ment in her symptoms of pruritus and temperament.
She tolerated the infusion of pamidronate well with no
adverse side effects.
Conclusion
We have demonstrated the effective use of pamidronate
as a single agent at a total dose of 1mg/kg to lower
serum calcium levels in a patient with severe hypercal-
cemia of malignancy. In such cases of severe hypercalce-
mia, we recommend the early use of pamidronate since
hydration with saline diuresis is unlikely to normalize
serum calcium levels effectively.
Written informed consent was obtained from the
patient for publication of this abstract and any accom-
panying images. A copy of the written consent is avail-
able for review by the Editor of this journal.
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